SALT LAKE CITY (August 16, 2022) – Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex, participated today in a fireside chat exploring approaches to innovate Alzheimer’s therapies at InformaConnect's Therapeutic Focus-Neurology digital conference.
“There is very little help available for people suffering from neuroinflammatory diseases, such as Alzheimer’s (AD). We do know that IL-1β signaling is connected to NLRP3-driven inflammation in AD patients”, said Jared Bearss, COO of Halia Therapeutics. “Halia’s therapeutic inhibitor of the NLRP3 inflammasome prevents the formation and promotes its disassembly once formed, thereby inhibiting the production and release of IL-1β and IL-18.”
Dr. David J. Bearss, CEO of Halia Therapeutics said, “Our lead therapeutic, at low nM concentrations, down-regulates proinflammatory cytokines which modulate neuroinflammatory disease. Further, it demonstrates significant in-vivo activity in mouse models, and we know that intranasal delivery of our therapeutic increases pharmacokinetic exposure in the central nervous system.” Dr. Bearss explained that NLRP3 inflammatory suppression looks promising as a key component to treat AD and the Halia compound represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases.
NLRP3 acts as an essential downstream effector of signals that trigger inflammatory responses and has been implicated in driving the onset and progression of many chronic inflammatory diseases. Activation of NLRP3 triggers the release of the pro-inflammatory cytokines IL-1β IL-18 and induces a lytic cell death process called pyroptosis. These processes lead to chronic inflammation. Persistent activation of the NLRP3 inflammasome is thought to drive the onset and progression of many conditions, including fibrotic, dermatological, and rheumatological diseases. Significant neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis are also driven by NLRP3 activation.
About Halia Therapeutics, Inc.
Halia Therapeutics, Inc. is headquartered in Salt Lake City, Utah, and is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases. Halia is advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. www.haliatherapeutics.com
Company Contact: Andi Groen, Info@haliatherapeutics.com, +1.385.355.4315,
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org, +1.858.344.8091